How many drugs are losing patent protection in 2022?

Drug Landscape tracks 2 marketed drugs with at least one patent expiring in 2022, sourced from FDA Orange Book + USPTO Patent Public Search.

What is a patent cliff?

A patent cliff is the year a major branded drug loses primary patent protection, opening the market to generic or biosimilar entry. Originator revenue typically drops 30–80% within 24 months, depending on the drug class and the strength of secondary patents.

Are these forecasts accurate?

Patent expiry dates are deterministic — they're the listed expiry from the Orange Book or USPTO record. Generic / biosimilar entry timing depends on litigation outcomes, paragraph IV challenges, settlements, and exclusivity periods which can shift the practical "cliff" by months to years.

Last reviewed 2026-05-15 · How we verify

2022 Pharmaceutical Patent Cliff

2 marketed drugs with patents expiring in 2022, joined to sponsor + therapeutic area + drug class. Historical archive. Sourced from FDA Orange Book + USPTO Patent Public Search.

2 drugs 2 patents 2 therapeutic areas Historical

Sponsors most affected (2)

AstraZeneca · 1 drug
University Hospital Schleswig-Holstein · 1 drug

By therapeutic area

Neuroscience (1)

2022-06-01 — Quetiapine 600mg · AstraZeneca · atypical antipsychotic

Immunology (1)

2022-06-01 — Fluvastatin, Tacrolimus, Mycophenolat Mofetil · University Hospital Schleswig-Holstein · ["Statins", "Immunosuppressants", "Immunosuppressants"]

Subscribe to patent-cliff alerts

Push every new patent expiry into your RSS reader:

Marketed-drug events RSS
All 2022 pharma events (approvals + readouts + patents)

Biosimilar tracker — who's competing for each post-cliff originator
Patent cliff revenue calculator
2022 patent expiries dataset (CSV / JSON)